SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Strategies & Market TrendsSpeculating in Takeover Targets


Previous 10 Next 10 
To: E_K_S who wrote (5742)12/20/2019 8:36:41 AM
From: robert b furman
   of 7078
 
Thanks E_K_S,

Important to remember the Healthy part.

I guess I'll have to consider a New Years resolution very soon.<smile>

Bob

Share RecommendKeepReplyMark as Last Read


From: E_K_S12/20/2019 8:37:21 AM
   of 7078
 
Johnson & Johnson to acquire remainder of Verb Surgical
Dec. 20, 2019 6:59 AM ET|

On the heels of its successful collaboration with Alphabet's Verily Life Sciences, Johnson & Johnson (NYSE: JNJ) has agreed to acquire the remaining stake in robotics and data science venture Verb Surgical for an undisclosed sum. The transaction should close in H1 2020.

Verb was a joint venture formed between J&J unit Ethicon and Google Life Sciences in late 2015.

Share RecommendKeepReplyMark as Last Read


From: E_K_S12/20/2019 8:57:45 AM
   of 7078
 
IAC acquiring Care.com for $500M; CRCM +13.5%
Dec. 20, 2019 8:53 AM ET|About: IAC/InterActiveCorp (IAC)

IAC (NASDAQ: IAC) will acquire Care.com (NYSE: CRCM) for $15 per share in cash.

The price represents an approximately $500M enterprise value and offers a 34% premium to the closing price on October 25, the last trading day before published M&A speculation.

IAC executive Tim Allen will become CRCM's new CEO.

After the expected deal close in Q1, Care.com will no longer trade on the NYSE.

CRCM shares are up 13.5% pre-market to $15.04

Share RecommendKeepReplyMark as Last Read


From: E_K_S12/20/2019 9:07:46 AM
   of 7078
 
Barnes to sell its Seeger-Orbis business
Dec. 20, 2019 9:05 AM ET|About: Barnes Group Inc. (B)|By: Jignesh Mehta, SA News Editor

Barnes (NYSE: B) has entered into a definitive agreement to sell its Seeger-Orbis business to the Kajo Neukirchen Group.

The transaction is expected to close in the 1Q20. Financial terms of the agreement were not disclosed.

Seeger develops and produces a comprehensive range of retaining rings, fasteners, snap rings and shims and generates annual revenues of ~$60M.

Share RecommendKeepReplyMark as Last Read


From: richardred12/20/2019 11:03:42 AM
   of 7078
 
Merry Christmas & Happy New Year to the board and all who celebrate the reason for the season.


Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (5740)12/23/2019 12:14:30 AM
From: richardred
   of 7078
 
RE-MNTX My GTC order was executed on Friday >5.10.

P.S. Maybe a omen from earlier in the year? Good or bad has yet to be determined. The company I work for had a big cooling unit put on the roof.


Share RecommendKeepReplyMark as Last Read


From: E_K_S12/23/2019 8:41:45 AM
   of 7078
 
AquaVenture +19.5% on $1.1B Culligan merger
Dec. 23, 2019 7:43 AM ET|

Culligan will acquire AquaVenture (NYSE: WAAS) for $27.10 per share in cash, a 25% premium to Friday's closing price.

The transaction is valued at approximately $1.1B, including net debt.

AquaVenture will become a privately held company and join Culligan's consumer water service and solutions platform.

The deal is expected to close in April 2020.

WAAS shares are up 19.5% pre-market to $26.

Share RecommendKeepReplyMark as Last Read


From: E_K_S12/23/2019 8:45:26 AM
   of 7078
 
Brookfield Infrastructure to buy Cincinnati Bell in $2.6B deal
Dec. 23, 2019 7:25 AM ET|

Cincinnati Bell (NYSE: CBB) agrees to be acquired by Brookfield Infrastructure (NYSE: BIP) in a deal valued at ~$2.6B including debt.

Under the deal terms, each CBB common share will be converted into the right to receive $10.50 in cash, which represents a 36% premium over last Friday's closing price and an 84% premium to the 60-day volume weighted average price.

"This investment represents an opportunity... to acquire a great franchise and leading fiber network operator in North America," says BIP CEO Sam Pollock.

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (5717)12/23/2019 10:01:58 AM
From: richardred
   of 7078
 
RE-ENZ speculation IMO why ENZ has potential





Roche to pay Sarepta $1B upfront for DMD gene therapy rights


by Nick Paul Taylor |
Dec 23, 2019 4:19am







Sarepta Therapeutics is in line to pocket up to $1.7 billion in regulatory and sales milestones, plus Roche is paying more than $1 billion upfront for the ex-U.S. rights to Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy SRP-9001. The deal comes days after Roche advanced its push into gene therapies by closing the takeover of Spark Therapeutics.

Sarepta has linked SRP-9001 to microdystrophin expression levels of up to 96% in early clinical tests, leading it to start a 24-patient placebo-controlled trial that is due to deliver data next year. Coupled to a safety profile that so far makes SRP-9001 look a better prospect than rival gene therapies from Pfizer and Solid Biosciences, the efficacy data have put Sarepta at the forefront of efforts to develop a one-shot treatment for DMD.

That has attracted the attention of Roche. The Swiss drugmaker is set to pay $750 million in cash and $400 million in equity upfront for the ex-U.S. rights to SRP-9001. Sarepta is also in line to pocket up to $1.7 billion in regulatory and sales milestones, plus royalties. Roche will pay half of global clinical development costs, although Sarepta will continue to handle the trials and manufacturing.

fiercebiotech.com

Share RecommendKeepReplyMark as Last Read


From: E_K_S12/24/2019 9:00:03 AM
   of 7078
 
Wesco offers to buy Anixter for $90/share
Dec. 24, 2019 8:48 AM ET|About: WESCO International, Inc. (WCC)|By: Carl Surran, SA News Editor

Wesco International (NYSE: WCC) +8.9% pre-market after jumping into the bidding for Anixter (NYSE: AXE) with a $90/share offer, a 2.8% premium to AXE's closing price yesterday.

AXE said yesterday it had agreed to a sweetened offer from P-E firm Clayton, Dubilier & Rice of $86/share in cash and a $2.50/share contingent value right.

AXE +2.1% pre-market.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)
Previous 10 Next 10